831PClinical experience with 100 consecutive patients treated with Lu-177-labeled PSMA-I&T radioligand therapy for metastatic castration-resistant prostate cancer: Final analysis. (23rd October 2018) - Tauber, R L; Knorr, K; Schwaiger, S; Retz, M; Maurer, T; D'Alessandria, C; Wester, H-J; Gschwend, J; Weber, W; Schwaiger, M; Heck, M M; Eiber, M